An observational study in Behçet's Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.
Among the 18 studies in Behcet Syndrome by Assiut University, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2026, is one of 14 observational ones, and was the 16th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 20–45
Assiut University
Ages 20–45
Assiut University
Ages 19–60 · Healthy volunteers
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Median enrollment 35 across the 4 interventional studies, 77 across the 14 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Behcet Syndrome by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07845162Assiut UniversitySerum EBI-3 Protein Levels in Behçet's Disease | 2027-09-26 |
| NCT07803198Assiut UniversityAsprosin in Behect Patients | 2027-09-30 |
| NCT07157189Assiut UniversityClinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Behcet Syndrome by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A cross-sectional, observational study surveying the clinical, laboratory, and therapeutic characteristics of Behçet's disease patients in a tertiary care center in Upper Egypt
This research is designed to comprehensively characterize Behçet's disease (BD), an inflammatory multisystem disorder with variable prevalence and presentation based on geography and ethnicity. Data will be collected from patients attending the Rheumatology, Rehabilitation and Physical Medicine department, Assiut University Hospitals, capturing demographic profiles, disease manifestations, laboratory results, and therapeutic history. The study uses validated criteria (ISG and rICBD) for BD diagnosis, focusing on thorough examination across musculoskeletal, dermatological, ocular, vascular, gastrointestinal, and neurological domains. Disease activity and severity will be assessed using standardized forms (Behcet's disease current activity form 2006, BODI). Laboratory analysis includes CBC, acute phase reactants, and organ function tests. Data management incorporates advanced statistical techniques using SPSS, aiming for rigorous analysis to inform future BD management in the region .
Eligible participants are adults and adolescents diagnosed using international criteria (ISG and rICBD), with recurrent oral ulceration and at least two additional manifestations (genital ulcers, eye lesions, skin lesions, positive pathergy test). Patients with unconfirmed BD are excluded. Given BD's variable age and gender distribution, the population will reflect regional epidemiological trends, including a probable male predominance consistent with Arab and Mediterranean cohorts. Comprehensive sociodemographic data, disease duration, age at onset, family/personal history, and clinical presentation are documented. All patients are monitored through a structured two-year inclusion, maximizing sample heterogeneity and capturing real-world data from both inpatient and outpatient clinical pathways .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
adults and adolescents diagnosed using international criteria (ISG and rICBD), with recurrent oral ulceration and at least two additional manifestations (genital ulcers, eye lesions, skin lesions, positive pathergy test).
Proportion of key clinical manifestations in Behçet's disease patients
This outcome will systematically quantify how often major clinical features-such as recurrent oral ulcers, genital ulcers, ocular lesions (including chronic relapsing uveitis), and musculoskeletal involvement, appear within the studied Behçet's disease population, in accordance with predefined diagnostic criteria
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
Start is estimated for Sep 2026; primary completion for Nov 2027, 14 months later.
Of 21 observational studies under Behcet Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 81. This study's planned 14 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.